Inari Medical, Inc. (NASDAQ:NARI) Director William Hoffman Sells 60,000 Shares

Inari Medical, Inc. (NASDAQ:NARI) Director William Hoffman sold 60,000 shares of the stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $55.66, for a total transaction of $3,339,600.00. Following the sale, the director now directly owns 441,233 shares in the company, valued at approximately $24,559,028.78. The trade was a 11.97 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

William Hoffman also recently made the following trade(s):

• On Monday, November 18th, William Hoffman sold 60,000 shares of Inari Medical stock. The stock was sold at an average price of $51.16, for a total value of $3,069,600.00.
• On Tuesday, October 29th, William Hoffman sold 40,000 shares of Inari Medical stock. The shares were sold at an average price of $50.05, for a total value of $2,002,000.00.
• On Wednesday, October 16th, William Hoffman sold 40,000 shares of Inari Medical stock. The stock was sold at an average price of $45.02, for a total value of $1,800,800.00.

Inari Medical Trading Down 2.0 %

NARI stock traded down $1.13 during trading on Wednesday, reaching $55.03. 1,297,859 shares of the stock were exchanged, compared to its average volume of 992,969. The firm has a market capitalization of $3.22 billion, a price-to-earnings ratio of -40.76 and a beta of 0.97. The business has a 50 day moving average price of $49.30 and a 200-day moving average price of $48.04. Inari Medical, Inc. has a 1 year low of $36.73 and a 1 year high of $67.10.

Analyst Ratings Changes

NARI has been the subject of a number of research analyst reports. Piper Sandler upped their price objective on shares of Inari Medical from $50.00 to $52.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 29th. Needham & Company LLC reiterated a “hold” rating on shares of Inari Medical in a report on Tuesday, October 29th. Canaccord Genuity Group increased their target price on Inari Medical from $71.00 to $74.00 and gave the company a “buy” rating in a report on Tuesday, October 29th. Leerink Partnrs raised shares of Inari Medical to a “hold” rating in a research note on Tuesday, September 3rd. Finally, Oppenheimer initiated coverage on shares of Inari Medical in a research note on Tuesday. They issued an “outperform” rating and a $75.00 price target on the stock. Six analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $61.80.

Institutional Trading of Inari Medical

Several institutional investors have recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC increased its stake in Inari Medical by 7.7% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 4,852 shares of the company’s stock worth $234,000 after acquiring an additional 348 shares during the last quarter. Arizona State Retirement System grew its holdings in shares of Inari Medical by 2.5% during the 2nd quarter. Arizona State Retirement System now owns 14,602 shares of the company’s stock worth $703,000 after purchasing an additional 358 shares during the period. Nisa Investment Advisors LLC increased its position in shares of Inari Medical by 83.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock worth $46,000 after purchasing an additional 435 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Inari Medical by 67.2% during the 3rd quarter. GAMMA Investing LLC now owns 1,177 shares of the company’s stock worth $49,000 after purchasing an additional 473 shares during the last quarter. Finally, KBC Group NV lifted its position in Inari Medical by 39.0% in the third quarter. KBC Group NV now owns 1,774 shares of the company’s stock valued at $73,000 after buying an additional 498 shares during the last quarter. Hedge funds and other institutional investors own 90.98% of the company’s stock.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.